Research Progress on the Mechanism of Jinxin Oral Liquid in Treating Respiratory Syncytial Virus

Respiratory syncytial virus is a major cause of pneumonia in the pediatric population. Currently, Western medicine lacks specific drugs to treat its infection, and there are relatively few related vaccines. Jinxin Oral Liquid, developed by Professor Wang Shouchuan, a renowned traditional Chinese medicine practitioner, is an experienced formula for treating viral pneumonia and has broad application prospects in the treatment of RSV pneumonia. It can treat syncytial virus infection by enhancing the immune response, suppressing excessive immune pathological and inflammatory responses, inhibiting the virus infection cycle, regulating cell apoptosis and metabolic disorders. This article aims to systematically elucidate the mechanism of Jinxin Oral Liquid against RSV infection and provide theoretical support for a comprehensive understanding of its antiviral scientific implications.